Systemic and coronary effects of intravenous milrinone and dobutamine in congestive heart failure
R Grose,
J Strain,
M Greenberg,
and
TH LeJemtel
The effects of dobutamine and intravenous milrinone on systemic hemodynamics, coronary blood flow and myocardial metabolism were studied in 11 patients with severe congestive heart failure. Although milrinone and dobutamine similarly increased cardiac index from 1.9 +/- 0.4 to 2.5 +/- 0.4 liters/min per m2 (p less than 0.001) and from 1.9 +/- 0.4 to 2.8 +/- 0.8 liters/min per m2 (p less than 0.001), respectively, milrinone decreased left ventricular end-diastolic pressure to a greater extent than dobutamine, that is, from 26 +/- 6 to 12 +/- 8 mm Hg (p less than 0.001) versus 26 +/- 8 to 20 +/- 8 mm Hg (p less than 0.001). In contrast to dobutamine, milrinone significantly reduced mean systemic arterial and right atrial pressures. Dobutamine increased the first derivative of left ventricular pressure (dP/dt) from 1,013 +/- 309 to 1,360 +/- 538 mm Hg/s (p less than 0.01) but milrinone did not. Similarly, blood flow and myocardial oxygen consumption were increased by dobutamine from 152 +/- 87 to 187 +/- 118 ml/min (p less than 0.05) and from 17.7 +/- 10.9 to 21.5 +/- 14.9 ml O2/min (p less than 0.05), respectively, but were unchanged by milrinone. Both drugs significantly decreased coronary vascular resistance and myocardial oxygen extraction but did not change myocardial lactate extraction. Thus, dobutamine and milrinone produce similar improvement in cardiac index. However, dobutamine increases myocardial oxygen consumption, whereas milrinone does not. This difference can probably be explained by the substantial vasodilating properties of milrinone.
This article has been cited by other articles:
|
|
|
|
 
F. Triposkiadis, G. Karayannis, G. Giamouzis, J. Skoularigis, G. Louridas, and J. Butler
The Sympathetic Nervous System in Heart Failure: Physiology, Pathophysiology, and Clinical Implications
J. Am. Coll. Cardiol.,
November 3, 2009;
54(19):
1747 - 1762.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Z. I. Khalpey, R. B. Ganim, and J. D. Rawn
Postoperative Care of Cardiac Surgery Patients
Card. Surg. Adult,
January 1, 2008;
3(2008):
465 - 486.
[Full Text]
|
|
|
|
|
|
|
W. T. Abraham, K. F. Adams, G. C. Fonarow, M. R. Costanzo, R. L. Berkowitz, T. H. LeJemtel, M. L. Cheng, J. Wynne, the ADHERE Scientific Advisory Committee Investiga, and and the ADHERE Study Group
In-Hospital Mortality in Patients With Acute Decompensated Heart Failure Requiring Intravenous Vasoactive Medications: An Analysis From the Acute Decompensated Heart Failure National Registry (ADHERE)
J. Am. Coll. Cardiol.,
July 5, 2005;
46(1):
57 - 64.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. D. Michaels, B. McKeown, M. Kostal, K. T. Vakharia, M. V. Jordan, I. L. Gerber, E. Foster, and K. Chatterjee
Effects of Intravenous Levosimendan on Human Coronary Vasomotor Regulation, Left Ventricular Wall Stress, and Myocardial Oxygen Uptake
Circulation,
March 29, 2005;
111(12):
1504 - 1509.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. D. Michaels, A. Klein, J. A. Madden, and K. Chatterjee
Effects of Intravenous Nesiritide on Human Coronary Vasomotor Regulation and Myocardial Oxygen Uptake
Circulation,
June 3, 2003;
107(21):
2697 - 2701.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. K. Pridjian, E. D. Frohlich, C. H. VanMeter, P. M. McFadden, and J. L. Ochsner
Pharmacologic support with high-energy phosphate preservation in the postischemic neonatal heart
Ann. Thorac. Surg.,
June 1, 1995;
59(6):
1435 - 1440.
[Abstract]
[PDF]
|
|
|
|
